Evidence map›Paper›PMID 34289926›Full record

ArticleJournal of the International Neuropsychological Society : JINS2022

Neuropsychological Profiles of Patients with Progressive Apraxia of Speech and Aphasia.

Angelina J Polsinelli, Mary M Machulda, Peter R Martin, Joseph R Duffy, Heather M Clark, Alissa M Butts, Hugo Botha, Val J Lowe, Jennifer L Whitwell, Keith A Josephs and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of the International Neuropsychological Society : JINS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. An Update on Apraxia of Speech.Current neurology and neuroscience reports · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Angelina J PolsinelliDepartment of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID 0000-0002-7738-9574
Mary M MachuldaDepartment of Psychiatry and Psychology, Division of Neuropsychology, Mayo Clinic, Rochester, MN, USA.
Peter R MartinDepartment of Biomedical Statistics & Informatics, Mayo Clinic, Rochester, MN, USA.
Joseph R DuffyDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Heather M ClarkDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Alissa M ButtsDepartment of Neurology, Division of Neuropsychology, Medical College of Wisconsin, Madison, WI, USA.
Hugo BothaDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Val J LoweDepartment of Neuroradiology, Mayo Clinic, Rochester, MN, USA.
Jennifer L WhitwellDepartment of Neuroradiology, Mayo Clinic, Rochester, MN, USA.
Keith A JosephsDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Rene L UtianskiDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Mayo Clinic in Arizona · USMayo Clinic · USIndiana University School of MedicineMayo Clinic in Florida · USMedical College of Wisconsin · US

Funding

Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI ADAM L. BOXER, Bradley F Boeve · 2019 to 2026
$120.9M
SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI BU, GUOJUN · 1999 to 2018
$36.9M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI Walter K. Kremers · 2019 to 2026
$33.5M
PREDICTING ALZHEIMERS DISEASE WITH MAGNETIC RESONANCER01AG011378 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R. · 1993 to 2017
$12.1M
Rochester Epidemiology ProjectR01AG034676 · NIA · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A, ST SAUVER, JENNIFER LYNN · 2010 to 2019
$9.5M
Longitudinal multi-modality imaging in progressive apraxia of speech (Diversity Supplement)R01DC012519 · NIDCD · MAYO CLINIC ROCHESTER · PI Jennifer Louise Whitwell · 2013 to 2026
$7.2M
Understanding the role of TDP-43 in Alzheimers disease and FTLDR01AG037491 · NIA · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A · 2010 to 2024
$6.5M
Validating the New Criteria for Preclinical Alzheimer's diseaseR01AG041851 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R., KNOPMAN, DAVID S · 2012 to 2021
$6.3M
Molecular and structural imaging in atypical Alzheimer's disease: a longitudinal studyR01AG050603 · NIA · MAYO CLINIC ROCHESTER · PI WHITWELL, JENNIFER LOUISE · 2016 to 2025
$5.9M
Longitudinal Multi-modal Imaging in Progressive Supranuclear Palsy SyndromesR01NS089757 · NINDS · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A, WHITWELL, JENNIFER LOUISE · 2015 to 2024
$5.6M
The neurobiology of two distinct types of progressive apraxia of speechR01DC014942 · NIDCD · MAYO CLINIC ROCHESTER · PI Keith A Josephs, Rene Lynn Utianski · 2017 to 2026
$4.9M
NIA NIH HHS P30 AG062677NIA NIH HHS P50 AG016574NIA NIH HHS R01 AG011378NIA NIH HHS R01 AG034676NIA NIH HHS R01 AG037491NIA NIH HHS R01 AG041851NIA NIH HHS R01 AG049810NIA NIH HHS R01 AG050603NIA NIH HHS R01 AG054449NIA NIH HHS U01 AG006786NIA NIH HHS U19 AG063911NIDCD NIH HHS R01 DC010367NIDCD NIH HHS R01 DC012519NIDCD NIH HHS R01 DC014942NINDS NIH HHS R01 NS089544NINDS NIH HHS R01 NS089757NINDS NIH HHS R01 NS097495NINDS NIH HHS R21 NS094489NINDS NIH HHS R21 NS094684
6 · The paper itself

Abstract

objectiveTo characterize and compare the neuropsychological profiles of patients with primary progressive apraxia of speech (PPAOS) and apraxia of speech with progressive agrammatic aphasia (AOS-PAA).

methodThirty-nine patients with PPAOS and 49 patients with AOS-PAA underwent formal neurological, speech, language, and neuropsychological evaluations. Cognitive domains assessed included immediate and delayed episodic memory (Wechsler Memory Scale-Third edition; Logical Memory; Visual Reproduction; Rey Auditory Verbal Learning Test), processing speed (Trail Making Test A), executive functioning (Trail Making Test B; Delis-Kaplan Executive Functioning Scale - Sorting), and visuospatial ability (Rey-Osterrieth Complex Figure copy).

resultsThe PPAOS patients were cognitively average or higher in the domains of immediate and delayed episodic memory, processing speed, executive functioning, and visuospatial ability. Patients with AOS-PAA performed more poorly on tests of immediate and delayed episodic memory and executive functioning compared to those with PPAOS. For every 1 unit increase in aphasia severity (e.g. mild to moderate), performance declined by 1/3 to 1/2 a standard deviation depending on cognitive domain. The degree of decline was stronger within the more verbally mediated domains, but was also notable in less verbally mediated domains.

conclusionThe study provides neuropsychological evidence further supporting the distinction of PPAOS from primary progressive aphasia and should be used to inform future diagnostic criteria. More immediately, it informs prognostication and treatment planning.

Indexed as

AphasiaAphasia, Primary ProgressiveApraxiasHumansLanguageNeuropsychological TestsSpeechAgrammatic aphasiaFrontotemporal dementiaMotor speech disorderNonfluent primary progressive aphasiaPrimary progressive aphasiaPrimary progressive apraxia of speech

Identifiers

PMID34289926
PMCPMC8986341
OpenAlexW3184703376

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.